About us:
We are Orb - A specialist investment deal-flow company with offices in London and Geneva. We work with global businesses and investors to identify off-book acquisition and investment opportunities.

Our core business is identifying opportunities where the acquirer/investor and the target companies can look to achieve a genuine win-win deal. We do this by working closely with our clients to understand which businesses will complement their growth strategy before identifying and reaching out to discuss the opportunity.

About this opportunity:
Antimicrobial resistance (AMR) is a growing global health threat, with 1.3 million people dying from antibiotic-resistant infections in 2019 alone. Traditional access to localised antimicrobial guidance has been inefficient, leading to overprescription of broad-spectrum antibiotics and a surge in drug-resistant pathogens.

The Solution
The business has revolutionised the way healthcare providers access and implement clinical guidance, policies, and procedures. First implemented at a UK University Hospital, where it led to a sustained reduction in high-risk broad-spectrum antibiotic prescriptions from 40% to 28%. The platform has since expanded to 75% of NHS Acute Hospitals and is now used in 13 different countries, totalling 170 medical organisations worldwide.

The Product
Offers a comprehensive and user-friendly Content Management System (CMS) for content editors, a mobile app for clinicians, and a web viewer for intranet access. The platform also includes a Decision Support Module (DSM) and a Patient Information Module (PIM), offering personalised drug regimens and patient-specific information, respectively.

Further Developments
The platform has evolved to manage a wide range of clinical guidance types and non-clinical documents such as policies and procedures. New modules, like the Import Bot and Governance Review Module (GRM), streamline content migration and management, making the product a one-stop-shop for healthcare organisations. The company has also developed an OPAT-Patient Management that supports nurses who are treating patients with antibiotics as outpatients, providing them access to a “Virtual Ward” where they can search and find current OPAT Patients, segment these patients into cohorts using a selection of pre-designed filters and update the patients’ record.

The PMS service could be adapted to help manage the treatment of generic conditions rather than just patients with infectious diseases.

The Opportunity
As a leader in combating AMR and improving clinical efficiency, the business presents a compelling acquisition opportunity for investors seeking a proven, scalable solution with significant growth potential in the global healthcare market.